Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

NCT02230306 is registered in ClinicalTrials.gov with Melissa Burgess, MD as lead sponsor.

NCT NCT02230306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02230306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Lead sponsor
Melissa Burgess, MD
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2015
Completion date
March 31, 2016
Enrollment
5 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

active melanoma brain metastases